Skip to content

US · NSPR · MEDICAL - DEVICES

InspireMD, Inc. (NSPR) intrinsic value and stock valuation

$0.54as of 2026-11-21 · Mkt cap 33.72M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

InspireMD, Inc. DCF and intrinsic value

InvestorsCraft values NSPR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NSPR’s statements →

InspireMD, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Miami, FL 33126 inspiremd.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$8.98M+29.3% 5y CAGRd
20112025
Net income
-$-48.79M
20112025
Free cash flow
-$-36.77M
20112025
Total equity
$55.2M+35.3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$8.98M$7.01M$6.21M$5.17M$4.5M
Operating income-$-49.11M-$-33.5M-$-21.14M-$-18.71M-$-14.72M
Net income-$-48.79M-$-32.01M-$-19.92M-$-18.49M-$-14.92M
EPSd-$-664.08K-$-763.42K-$-820.77K-$-2.35M-$-2.03M
Operating cash flow-$-35.1M-$-21.87M-$-16.38M-$-15.54M-$-13.21M
Capital expenditure-$-1.66M-$-1.4M-$-380K-$-470K-$-340K
Free cash flow-$-36.77M-$-23.27M-$-16.76M-$-16.02M-$-13.55M
Total assets$69.4M$46.8M$47.6M$24.7M$39.7M
Total debt$3.29M$2.34M$1.59M$1.61M$1.2M
Net debt-$-5.65M-$-16.58M-$-8.04M-$-3.02M-$-10.8M
Total equity$55.2M$36.1M$39.5M$17.4M$33.5M
Cash and short-term investments$54.2M$34.6M$39M$17.8M$34M
Income statement
20252024202320222021
Revenue$8.98M$7.01M$6.21M$5.17M$4.5M
Cost of revenue$6.33M$5.5M$4.4M$4.05M$3.74M
Gross profit$2.65M$1.51M$1.81M$1.12M$750K
Research and development expenses$15M$13.6M$7.98M$7.81M$5.16M
Selling, general and administrative expenses$37.3M$21.4M$15M$12M$10.3M
Other expenses-$-500K$0.00$0.00$0.00$0.00
Operating expenses$51.8M$35M$23M$19.8M$15.5M
Cost and expenses$58.1M$40.5M$27.4M$23.9M$19.2M
Interest income$0.00$1.56M$1.29M$250K$0.00
Interest expense$0.00$0.00$0.00$0.00$160K
Depreciation and amortization$480K$280K$230K$190K$160K
Ebitda-$-48.25M-$-31.67M-$-19.62M-$-18.27M-$-14.55M
Operating income-$-49.11M-$-33.5M-$-21.14M-$-18.71M-$-14.72M
Total other income/expenses, net$390K$1.56M$1.29M$250K-$-160K
Income before tax-$-48.72M-$-31.95M-$-19.85M-$-18.46M-$-14.87M
Income tax expense$60K$60K$70K$30K$40K
Net income-$-48.79M-$-32.01M-$-19.92M-$-18.49M-$-14.92M
Weighted average shares outstanding$73.5M$41.9M$24.3M$7.87M$7.35M
Weighted average diluted shares outstanding$73.5M$41.9M$24.3M$7.87M$7.35M
Balance sheet
20252024202320222021
Cash and short-term investments$54.2M$34.6M$39M$17.8M$34M
Net receivables$2.57M$2.25M$2.45M$1.25M$1.39M
Inventory$3.4M$2.57M$2.11M$1.62M$1.14M
Total current assets$61.5M$40.5M$44.2M$21.3M$37.1M
Property, plant and equipment, net$6.34M$4.73M$2.53M$2.47M$1.71M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$7.93M$6.29M$3.48M$3.33M$2.62M
Total assets$69.4M$46.8M$47.6M$24.7M$39.7M
Accounts payable$1.25M$1.25M$940K$660K$890K
Short-term debt$1.07M$540K$560K$420K$420K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$10.7M$7.68M$6.02M$5.07M$4.35M
Long-term debt$2.22M$1.8M$1.04M$1.2M$780K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$3.49M$3.04M$2.12M$2.19M$1.83M
Capital lease obligations$3.29M$2.34M$1.59M$1.61M$1.2M
Total liabilities$14.2M$10.7M$8.14M$7.26M$6.18M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-302.29M-$-253.51M-$-221.5M-$-201.59M-$-183.09M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$55.2M$36.1M$39.5M$17.4M$33.5M
Total investments$45.3M$15.7M$29.4M$13.2M$22M
Total debt$3.29M$2.34M$1.59M$1.61M$1.2M
Net debt-$-5.65M-$-16.58M-$-8.04M-$-3.02M-$-10.8M
Cash flow statement
20252024202320222021
Net income-$-48.79M-$-32.01M-$-19.92M-$-18.49M-$-14.92M
Depreciation and amortization$480K$280K$230K$190K$160K
Stock-based compensation$12.3M$10.1M$4.49M$2.35M$1.58M
Change in working capital$1.11M$740K-$-800K$400K-$-70K
Accounts receivable-$-310K$200K-$-1.21M$140K-$-750K
Inventory-$-830K-$-460K-$-480K-$-480K$270K
Accounts payable$0.00$320K$280K-$-230K$660K
Net cash provided by operating activities-$-35.1M-$-21.87M-$-16.38M-$-15.54M-$-13.21M
Investments in property, plant and equipment-$-1.66M-$-1.4M-$-380K-$-470K-$-340K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-30.56M$12.6M-$-16.09M$8.44M-$-22.46M
Common stock issued$55.6M$1.6M$37.5M$0.00$35M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$55.6M$18.5M$37.5M-$-140K$35M
Net change in cash-$-9.98M$9.28M$5.01M-$-7.37M-$-640K
Cash at end of period$8.94M$18.9M$9.64M$4.63M$12M
Operating cash flow-$-35.1M-$-21.87M-$-16.38M-$-15.54M-$-13.21M
Capital expenditure-$-1.66M-$-1.4M-$-380K-$-470K-$-340K
Free cash flow-$-36.77M-$-23.27M-$-16.76M-$-16.02M-$-13.55M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About InspireMD, Inc.

        InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary interventions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.

        CEO
        Marvin L. Slosman
        Employees
        127
        Beta
        0.78

        Explore

        Frequently asked questions

        What is the intrinsic value of InspireMD, Inc. (NSPR)?

        InvestorsCraft does not currently publish an intrinsic value for NSPR. How the IC value is calculated.

        Is NSPR undervalued?

        InvestorsCraft does not publish an undervaluation signal for NSPR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.